Isavuconazonium, the water-soluble pro-drug of isavuconazole, is developed by Basilea Pharmaceutica. Isavuconazole, like other azoles, inhibits ergosterol synthesis and is a water-soluble compound with both oral and intravenous formulations. It has excellent bioavailability and a long elimination half-life, allowing for once-weekly dosing. It is the only broad-spectrum water-soluble triazole available.
